Cited by 347Psychedelics and Drug StudiesForensic Toxicology and Drug AnalysisSubstance Abuse Treatment and Outcomes

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Psychedelics and Mental Health: A Population Study

Open access

Krebs, Teri S., Johansen, Pål-Ørjan·2013·PLoS ONE

DOI 10.1371/journal.pone.0063972PMC PMC3747247

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The classical serotonergic psychedelics LSD, psilocybin, mescaline are not known to cause brain damage and are regarded as non-addictive. Clinical studies do not suggest that psychedelics cause long-term mental health problems. Psychedelics have been used in the Americas for thousands of years. Over 30 million people currently living in the US have used LSD, psilocybin, or mescaline. OBJECTIVE: To evaluate the association between the lifetime use of psychedelics and current mental health in the adult population. METHOD: Data drawn from years 2001 to 2004 of the National Survey on Drug Use and Health consisted of 130,152 respondents, randomly selected to be representative of the adult population in the United States. Standardized screening measures for past year mental health included serious psychological distress (K6 scale), mental health treatment (inpatient, outpatient, medication, needed but did not receive), symptoms of eight psychiatric disorders (panic disorder, major depressive episode, mania, social phobia, general anxiety disorder, agoraphobia, posttraumatic stress disorder, and non-affective psychosis), and seven specific symptoms of non-affective psychosis. We calculated weighted odds ratios by multivariate logistic regression controlling for a range of sociodemographic variables, use of illicit drugs, risk taking behavior, and exposure to traumatic events. RESULTS: 21,967 respondents (13.4% weighted) reported lifetime psychedelic use. There were no significant associations between lifetime use of any psychedelics, lifetime use of specific psychedelics (LSD, psilocybin, mescaline, peyote), or past year use of LSD and increased rate of any of the mental health outcomes. Rather, in several cases psychedelic use was associated with lower rate of mental health problems. CONCLUSION: We did not find use of psychedelics to be an independent risk factor for mental health problems.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0063972

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Screening for serious mental illness in the general population
Kessler, R. C., Barker, P. R., Colpe, L. J., Epstein, J. F., Gfroerer, J. C., Hiripi, E., Howes, M. J., Normand, S.-L. T., Manderscheid, R. W., Walters, E. E., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.2.184 · Cited by 5,692
Relaxing the Rule of Ten Events per Variable in Logistic and Cox Regression
Vittinghoff, E., & McCulloch, C. E. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwk052 · Cited by 4,359
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Lifetime Prevalence of Psychotic and Bipolar I Disorders in a General Population
Perälä, J., Suvisaari, J., Saarni, S. I., Kuoppasalmi, K. I., Isometsä, E. T., Pirkola, S. P., Partonen, T., Tuulio‐Henriksson, A., Hintikka, J., Kieseppä, T., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.1.19 · Cited by 1,523
Development of a rational scale to assess the harm of drugs of potential misuse
Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60464-4 · Cited by 1,302 · cited 1×
“LSD and psilocybin are consistently ranked in expert assessments as causing less harm to both individual users and society than alcohol, tobacco, and most other common recreational drugs [16–19].”
Background
European Monitoring Centre for Drugs and Drug Addiction
Anderson, M. (2014) · European Union regulations | European Encyclopedia of law · Cited by 1,214
Hallucinogens
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905

Flagged first, then by citations

Show all 58 references

Research works printed but not linked: 1

Laing R, Siegel JA, editors (2003) Hallucinogens: A Forensic Drug Handbook. Academic Press.

Sorted by citations

Items 101–200 of 345

Current Perspective on the Therapeutic Preset for Substance-Assisted Psychotherapy
Thal, S. B., Bright, S. J., Sharbanee, J. M., Wenge, T., & Skeffington, P. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.617224 · Cited by 38
Psychedelic treatment of functional neurological disorder: a systematic review
Butler, M., Seynaeve, M., Nicholson, T. R., Pick, S., Kanaan, R., Lees, A. J., Young, A. H., & Rucker, J. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320912125 · Cited by 39
Role of psilocybin in the treatment of depression
Mahapatra, A., & Gupta, R. G. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316676092 · Cited by 42
Psilocybin history, action and reaction: A narrative clinical review
Sharma, P., Nguyen, Q. A., Matthews, S. J., Carpenter, E., Matthews, D. B., Patten, C. A., & Hammond, C. J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231190858 · Cited by 44
The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women
Argento, E., Braschel, M. C., Walsh, Z., Socias, M. E., & Shannon, K. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118798610 · Cited by 38
The History of Psychedelics in Medicine
Sessa, B. (2016) · Springer eBooks · doi:10.1007/978-3-642-55214-4_96-1 · Cited by 44
Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002–2019
Walsh, C. A., Livne, O., Shmulewitz, D., Stohl, M., & Hasin, D. S. (2022) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2022.100454 · Cited by 37
Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis
Dourron, H. M., Strauss, C. K., & Hendricks, P. S. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000514 · Cited by 35
Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults
Yang, K. H., Han, B. H., & Palamar, J. J. (2022) · Addictive Behaviors · doi:10.1016/j.addbeh.2022.107343 · Cited by 38
Trends in DMT and other tryptamine use among young adults in the United States
Palamar, J. J., & Le, A. (2018) · American Journal on Addictions · doi:10.1111/ajad.12803 · Cited by 35
Psychedelic use and psychiatric risks
Simonsson, O., Goldberg, S. B., Chambers, R., Osika, W., Simonsson, C., & Hendricks, P. S. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06478-5 · Cited by 36
A Systematic Review of Participant Diversity in Psychedelic-Assisted Psychotherapy Trials
Haft, S. L., Downey, A. E., Raymond‐Flesch, M., Fernandes‐Osterhold, G., Bradley, E., O’Donovan, A., & Woolley, J. D. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2025.116359 · Cited by 38
Psychedelics in the treatment of unipolar and bipolar depression
Bosch, O. G., Halm, S., & Seifritz, E. (2022) · International Journal of Bipolar Disorders · doi:10.1186/s40345-022-00265-5 · Cited by 38
How do serotonergic psychedelics treat depression: The potential role of neuroplasticity
Artin, H., Zisook, S., & Ramanathan, D. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i6.201 · Cited by 33
An Overview on the Taxonomy, Phylogenetics and Ecology of the Psychedelic Genera Psilocybe, Panaeolus, Pluteus and Gymnopilus
Strauss, D., Ghosh, S. B., Murray, Z., & Gryzenhout, M. (2022) · Frontiers in Forests and Global Change · doi:10.3389/ffgc.2022.813998 · Cited by 33
A Public-Health-Based Vision for the Management and Regulation of Psychedelics
Haden, M., Emerson, B., & Tupper, K. W. (2016) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2016.1202459 · Cited by 39
Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting
Argento, E., Socias, M. E., Hayashi, K., Choi, J., Mackay, L., Christie, D., Milloy, M., & DeBeck, K. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103518 · Cited by 35
Drug policy, values and the public health approach –four lessons from drug policy reform movements
Røgeberg, O. J. (2015) · Nordic Studies on Alcohol and Drugs · doi:10.1515/nsad-2015-0034 · Cited by 32
Lifetime use of psychedelics is associated with better mental health indicators during the COVID-19 pandemic
Cavanna, F., Pallavicini, C., Milano, V., Cuiule, J. I., Tella, R. D., González, P., & Tagliazucchi, E. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00172 · Cited by 34
American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey
Barnett, B. S., Arakelian, M. H., Beebe, D. S., Ontko, J., Riegal, C., Siu, W. O., Weleff, J., & Pope, H. G. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0036 · Cited by 31
Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland
Kangaslampi, S., Hausen, A., & Rauteenmaa, T. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1767321 · Cited by 31
Neuropsychiatric Disorders: Bridging the Gap Between Neurology and Psychiatry
Taslim, S., Shadmani, S., Saleem, A. R., Kumar, A., Brahma, F., Blank, N., Bashir, M. A., Ansari, D., Kumari, K., Tanveer, M. U., et al. (2024) · Cureus · doi:10.7759/cureus.51655 · Cited by 29
Retracted
Psilocybin occasioned mystical‐type experiences
James, E., Robertshaw, T. L., Hoskins, M. D., & Sessa, B. (2020) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2742 · Cited by 36
Inside bad trips: Exploring extra-pharmacological factors
Oña, G. (2018) · Journal of Psychedelic Studies · doi:10.1556/2054.2018.001 · Cited by 26
Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential
Rucker, J. (2015) · BMJ · doi:10.1136/bmj.h2902 · Cited by 28
Mental health of a self-selected sample of psychedelic users and self-medication practices with psychedelics
Mason, N. L., & Kuypers, K. P. C. (2018) · Journal of Psychedelic Studies · doi:10.1556/2054.2018.006 · Cited by 28
When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research
Jacobs, E., Murphy-Beiner, A., Rouiller, I., Nutt, D. J., & Spriggs, M. J. (2023) · Neuroethics · doi:10.1007/s12152-023-09536-z · Cited by 31
Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials
Fang, S., Yang, X., & Zhang, W. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1359088 · Cited by 34
Moral Enhancement Requires Multiple Virtues
Hughes, J. J. (2014) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180114000334 · Cited by 32
Medical student attitudes and perceptions of psychedelic-assisted therapies
Li, I., Fong, R., Hagen, M. M., & Tabaac, B. J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1190507 · Cited by 27
Apophenia, absorption and anxiety: Evidence for individual differences in positive and negative experiences of Hallucinogen Persisting Perceptual Disorder
Irvine, A., & Luke, D. P. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00195 · Cited by 25
Psychedelic Science, Contemplative Practices, and Indigenous and Other Traditional Knowledge Systems: Towards Integrative Community-Based Approaches in Global Health
Urrutia, J., Anderson, B. T., Belouin, S. J., Berger, A. M., Griffiths, R. R., Grob, C. S., Henningfield, J. E., Labate, B. C., Maier, L. J., Maternowska, M. C., et al. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2258367 · Cited by 29
Use of Lysergic Acid Diethylamide by Major Depression Status
Walsh, C. A., Gorfinkel, L., Shmulewitz, D., Stohl, M., & Hasin, D. S. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.3867 · Cited by 26
Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey
Bonnelle, V., Smith, W., Mason, N. L., Cavarra, M., Kryskow, P., Kuypers, K. P. C., Ramaekers, J. G., & Feilding, A. (2022) · British Journal of Pain · doi:10.1177/20494637221114962 · Cited by 26
Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder
Myran, D. T., Pugliese, M., Xiao, J., Kaster, T. S., Husain, M. I., Anderson, K. K., Fabiano, N., Wong, S., Fiedorowicz, J. G., Webber, C., et al. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.3532 · Cited by 25
The ethics of psychedelic research in disorders of consciousness
Peterson, A. H., Tagliazucchi, E., & Weijer, C. (2019) · Neuroscience of Consciousness · doi:10.1093/nc/niz013 · Cited by 25
Adverse psychiatric effects of psychedelic drugs: a systematic review of case reports
Yildirim, B., Sahin, S. S., Gee, A., Jauhar, S., Rucker, J., Salgado‐Pineda, P., Pomarol‐Clotet, E., & McKenna, P. J. (2024) · Psychological Medicine · doi:10.1017/s0033291724002496 · Cited by 28
Hallucinogen use is associated with mental health and addictive problems and impulsivity in university students
Grant, J. E., Lust, K. A., & Chamberlain, S. R. (2019) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2019.100228 · Cited by 24
Psychological effects of psychedelics in adolescents
Izmi, N., Carhart-Harris, R. L., & Kettner, H. (2024) · Frontiers in Child and Adolescent Psychiatry · doi:10.3389/frcha.2024.1364617 · Cited by 26
The link between use of psychedelic drugs and mental health problems
Nesvåg, R., Bramness, J. G., & Ystrøm, E. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115596156 · Cited by 23
Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money
Humphreys, K. N., Korthuis, P. T., Stjepanović, D., & Hall, W. (2024) · Annual Review of Psychology · doi:10.1146/annurev-psych-020124-023532 · Cited by 26
Race, Ethnic, and Sex Differences in Prevalence of and Trends in Hallucinogen Consumption Among Lifetime Users in the United States Between 2015 and 2019
Davis, A. K., Arterberry, B. J., Xin, Y., Agin-Liebes, G., Schwarting, C. M., & Williams, M. T. (2022) · Frontiers in Epidemiology · doi:10.3389/fepid.2022.876706 · Cited by 22
Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder
Ledwos, N., Rodas, J. D., Husain, M. I., Feusner, J. D., & Castle, D. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221140009 · Cited by 28
The psychedelic renaissance: the next trip for psychiatry?
Kelly, J. R., Baker, A., Babiker, M., Burke, L., Brennan, C., & O’Keane, V. (2019) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2019.39 · Cited by 21
Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial)
Jensen, M. E., Stenbæk, D. S., Juul, T. S., Fisher, P. M., Ekstrøm, C. T., Knudsen, G. M., & Fink‐Jensen, A. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-066019 · Cited by 25
Ceremonial ‘Plant Medicine’ use and its relationship to recreational drug use: an exploratory study
Dorsen, C. G., Palamar, J. J., & Shedlin, M. G. (2018) · Addiction Research & Theory · doi:10.1080/16066359.2018.1455187 · Cited by 23
Turn on and tune in to evidence-based psychedelic research
Sessa, B. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00120-5 · Cited by 22
Psychedelic drug use and schizotypy in young adults
Lebedev, A. V., Acar, K., Garzón, B., Almeida, R., Raback, J., Åberg, A., Martinsson, S., Olsson, A., Louzolo, A., Pärnamets, P., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94421-z · Cited by 19
Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives
Kaypak, A. C., & Raz, A. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221119386 · Cited by 22
Psychedelic-assisted psychotherapy for the treatment of major depression: a synthesis of phenomenological explanations
McMillan, R. M., & Jordens, C. F. C. (2022) · Medicine Health Care and Philosophy · doi:10.1007/s11019-022-10070-7 · Cited by 19
The Power of Social Attribution: Perspectives on the Healing Efficacy of Ayahuasca
de Mori, B. B. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.748131 · Cited by 21
Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample
Mellner, C., Dahlén, M., & Simonsson, O. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191811353 · Cited by 18
Psychédéliques, psychothérapie et symbolisation : une revue de littérature dans le champ de la dépression
Artru, E., & Rabeyron, T. (2021) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2021.03.013 · Cited by 20
Psilocybin as a novel treatment for chronic pain
Askey, T., Lasrado, R., Maiarù, M., & Stephens, G. J. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17420 · Cited by 18
A dose of therapy with psilocybin - A meta-analysis of the relationship between the amount of therapy hours and treatment outcomes in psychedelic-assisted therapy
Hultgren, J., Hafsteinsson, M. H., & Brulin, J. G. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.07.020 · Cited by 17
A survey of Australian psychiatrists’ and psychiatry trainees’ knowledge of and attitudes towards psychedelics in the treatment of psychiatric disorders
Grover, C., Monds, L. A., & Montebello, M. E. (2023) · Australasian Psychiatry · doi:10.1177/10398562231155125 · Cited by 16
New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues
Schifano, F., Napoletano, F., Chiappini, S., Orsolini, L., Guirguis, A., Corkery, J., Bonaccorso, S., Ricciardi, A., Scherbaum, N., & Vento, A. E. (2019) · Current Addiction Reports · doi:10.1007/s40429-019-00249-z · Cited by 19
Utilizing Psychedelics to Enhance Well-Being: A Systematic Review
Thomson, S., & Thomacos, N. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2484380 · Cited by 16
A Brief Review on the Potential of Psychedelics for Treating Alzheimer’s Disease and Related Depression
Pilozzi, A. R., Foster, S. L., Mischoulon, D., D, M. F. M., & Huang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512513 · Cited by 15
Psychedelics, Mystical Experiences, and Meaning Making: A Renegotiation Process With the Challenges of Existence
Hearn, B. (2021) · The Journal of Humanistic Counseling · doi:10.1002/johc.12164 · Cited by 18
LSD treatment in Scandinavia: emphasizing indications and short-term treatment outcomes of 151 patients in Denmark
Larsen, J. K. (2017) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2017.1336251 · Cited by 15
Psychedelic drugs in the treatment of anxiety, depression and addiction
Kvam, T.-M., Stewart, L. H., & Andreassen, O. A. (2018) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.17.1110 · Cited by 15
Police perceptions of eyewitness impairment due to alcohol and other drug use: a cross-cultural comparison
Monds, L. A., Cullen, H. J., Kloft, L., Sumampouw, N. E. J., van Golde, C., Harrison, A. W., & Otgaar, H. (2021) · Police Practice and Research · doi:10.1080/15614263.2021.1979397 · Cited by 14
The association between naturalistic use of psychedelics and co-occurring substance use disorders
Rabinowitz, J., Lev‐Ran, S., & Gross, R. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1066369 · Cited by 15
Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders
Wong, S., Yu, A. Y., Fabiano, N., Finkelstein, O., Pasricha, A., Jones, B. D. M., Rosenblat, J. D., Blumberger, D. M., Mulsant, B. H., & Husain, M. I. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2251133 · Cited by 15
Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer
Barnett, B. S., & Greer, G. R. (2021) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2020.12.011 · Cited by 13
Psilocybin containing mushrooms: a rapidly developing biotechnology industry in the psychiatry, biomedical and nutraceutical fields
Strauss, D., Ghosh, S. B., Murray, Z., & Gryzenhout, M. (2022) · 3 Biotech · doi:10.1007/s13205-022-03355-4 · Cited by 15
Differences in attitudes and beliefs about psychedelic-assisted therapy among social workers, psychiatrists, and psychologists in the United States
Armstrong, S. B., Levin, A. W., Xin, Y., Horan, J., Luoma, J. B., Nagib, P. B., Pilecki, B. C., & Davis, A. K. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00245 · Cited by 13
5-Methoxy-N,N-dimethyltryptamine: An Ego-Dissolving Endogenous Neurochemical Catalyst of Creativity
Germann, C. B. (2019) · Activitas Nervosa Superior · doi:10.1007/s41470-019-00063-y · Cited by 14
A potential role for psilocybin in the treatment of obsessive-compulsive disorder
Jacobs, E. (2020) · Journal of Psychedelic Studies · doi:10.1556/2054.2020.00128 · Cited by 17
Proposing a “Brain Health Checkup (BHC)” as a Global Potential “Standard of Care” to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of “Dopamine Homeostasis”
Braverman, E. R., Dennen, C. A., Gold, M. S., Bowirrat, A., Gupta, A., Baron, D. A., Roy, A., Smith, D. E., Cadet, J. L., & Blum, K. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19095480 · Cited by 14
Neurobiology of the Effects of Psilocybin in Relation to Its Potential Therapeutic Targets
Tylš, F., Páleníček, T., & Horáček, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00073-x · Cited by 14
Influence of depressive symptoms on distress related to positive psychotic-like experiences in women
Brañas, A., Barrigón, M. L., Lahera, G., Canal‐Rivero, M., & Ruíz-Veguilla, M. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.08.094 · Cited by 13
Pattern Breaking: A Complex Systems Approach to Psychedelic MedicinePreprint
Hipólito, I., Mago, J., Rosas, F. E., & Carhart-Harris, R. L. (2022) · doi:10.31234/osf.io/ydu3h · Cited by 13
Prophylactic action of ayahuasca in a non-human primate model of depressive-like behavior
Grilo, M. L. P. D. M., de Sousa, G. M., de Mendonça, L. A. C., Soares, B. L., de Sousa, M. B. C., Palhano-Fontes, F., de Araújo, D. B., Perkins, D., Hallak, J. E. C., & Coelho, N. L. G. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.901425 · Cited by 16
Psychedelic Therapy: A Primer for Primary Care Clinicians—Lysergic Acid Diethylamide (LSD)
Beutler, B. D., Shinozuka, K., Tabaac, B. J., Arenas, A., Cherian, K. N., Evans, V. D., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001726 · Cited by 13
Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder
Szafoni, S., Gręblowski, P., Grabowska, K., & Więckiewicz, G. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1406888 · Cited by 16
Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use
Zhou, K., de Wied, D., Carhart-Harris, R. L., & Kettner, H. (2025) · PNAS Nexus · doi:10.1093/pnasnexus/pgae560 · Cited by 23
Deep CANALs: a deep learning approach to refining the canalization theory of psychopathology
Juliani, A., Safron, A., & Kanai, R. (2024) · Neuroscience of Consciousness · doi:10.1093/nc/niae005 · Cited by 12
Psilocybin: Psychotherapy or drug?
Goodwin, G. M. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675757 · Cited by 12
The potential of psilocybin use to enhance well-being in healthy individuals – A scoping review
Wiepking, L., de Bruin, E. J., & Ghiţă, A. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00244 · Cited by 12
Focusing on the negative: cases of long-term negative psychological responses to psychedelicsPreprint
Bremler, R., Katati, N., Shergill, P., Erritzøe, D., & Carhart-Harris, R. L. (2023) · doi:10.31234/osf.io/yzmcj · Cited by 11
Have Norwegians tried psilocybin, and do they accept it as a medicine?
Jacobsen, H. B., Stubhaug, A., Holmøy, B., Kvam, T.-M., & Rème, S. E. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00167 · Cited by 10
Le traitement médiatique du LSD en France en 1966 : de la panique morale à la fin des études cliniques
Dubus, Z. (2022) · Cygne noir · doi:10.7202/1091460ar · Cited by 10
Modern pharmacotherapy guidance for treating alcohol use disorders
Soyka, M., & Rösner, S. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2445734 · Cited by 11
Therapeutic Potential of Psilocybin for Treating Psychological Distress among Survivors of Adverse Childhood Experiences: Evidence on Acceptability and Potential Efficacy of Psilocybin Use
Card, K. G., Grewal, A., Closson, K., Martin, G., Baracaldo, L., Allison, S., Kruger, D. J., & Walsh, Z. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2268640 · Cited by 10
Human biodistribution and radiation dosimetry of the 5-HT2A receptor agonist Cimbi-36 labeled with carbon-11 in two positions
Johansen, A., Holm, S., Dall, B., Keller, S., Kristensen, J. L., Knudsen, G. M., & Hansen, H. D. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0527-4 · Cited by 10
Psychotherapie mit adjuvanter Gabe von serotonergen psychoaktiven Substanzen – Möglichkeiten und Hindernisse
Majić, T., Jungaberle, H., Schmidt, T. T., Zeuch, A., Hermle, L., & Gallinat, J. (2017) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-0043-103085 · Cited by 10
Perceived attachment history predicts psychedelic experiences: A naturalistic study
Cherniak, A. D., Mikulincer, M., Brulin, J. G., & Granqvist, P. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00330 · Cited by 10
Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey
Stroud, J., Rice, C., Orsini, A., Schlosser, M., Lee, J., Mandy, W., & Kamboj, S. K. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06685-8 · Cited by 11
Recreation and Realization: Reported Motivations of Use Among Persons Who Consume Psychedelics in Non-Clinical Settings
Dollar, C. B. (2021) · doi:10.21428/88de04a1.cb6fef95 · Cited by 10
Hallucinations and Hallucinogens: Psychopathology or Wisdom?
Bouso, J. C., Oña, G., Kohek, M., SANTOS, R. G. D., Hallak, J. E. C., Alcázar‐Córcoles, M. Á., & Obiols‐Llandrich, J. (2023) · Culture Medicine and Psychiatry · doi:10.1007/s11013-022-09814-0 · Cited by 15
Psychedelics and the Entropic Brain Beyond the Self
Eyghen, H. V. (2023) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2023.2192078 · Cited by 11
Evidence versus expectancy: the development of psilocybin therapy
Rucker, J. (2023) · BJPsych Bulletin · doi:10.1192/bjb.2023.28 · Cited by 9
Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic
Bouso, J. C., Révész, D., Oña, G., Rossi, G. N., Rocha, J. M., SANTOS, R. G. D., Hallak, J. E. C., & Alcázar‐Córcoles, M. Á. (2023) · Scientific Reports · doi:10.1038/s41598-023-41199-x · Cited by 9
Deepening Psychedelic Integration: Exploring Complex Settings, Understanding User’s Struggles, and Implementing Safe Interventions
Aixalà, M. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_532 · Cited by 9
The link between childhood trauma and dissociation in frequent users of classic psychedelics and dissociatives
Thal, S. B., Daniels, J. K., & Jungaberle, H. (2019) · Journal of Substance Use · doi:10.1080/14659891.2019.1614234 · Cited by 9
Psilocybin alters brain activity related to sensory and cognitive processing in a time-dependent mannerPreprint
Nikolič, M., Mediano, P. A. M., Froese, T., Reydellet, D., & Páleníček, T. (2024) · medRxiv · doi:10.1101/2024.09.09.24313316 · Cited by 10
Hallucinogen Use and Misuse in Older Adults
Redden, W. M., Paracha, S.-U.-R., & Sheheryar, Q. (2021) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2021.07.007 · Cited by 8
On the mushrooming reports of “quiet quitting”: Employees’ lifetime psilocybin use predicts their overtime hours worked
Korman, B. A. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2242358 · Cited by 8

Authors: Krebs, T. S., & Johansen, P.-Ø.
Affiliations: Norwegian University of Science and Technology (NO)
Corresponding author: Krebs, Teri S.
Venue: PLoS ONE
Publisher: Public Library of Science (PLoS)
Published: 2013-08-19
Volume: 8
Issue: 8
Pages: e63972
ISSN: 1932-6203 (ISSN-L)
DOI: 10.1371/journal.pone.0063972
PMC: PMC3747247
OpenAlex: W2014761647
Cited by: 347
References: 58
Citations by year: 2026: 24 · 2025: 25 · 2024: 37 · 2023: 53 · 2022: 40 · 2021: 41 · 2020: 17 · 2019: 17 · 2018: 30 · 2017: 19 · 2016: 20 · 2015: 16 · 2014: 6 · 2013: 2
FWCI: 16.32
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: PLoS ONE (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
Funders: Norges Forskningsråd (rcn-foriss-185924)
Substance Abuse and Mental Health Services Administration
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords: psychedelics, LSD, psilocybin, mescaline, peyote, mental health, serious psychological distress, mental illness, non-affective psychosis, lifetime drug use, risk factors for mental illness, National Survey on Drug Use and Health
MeSH terms: Adolescent, Adult, Mental Disorders, Data Collection, Female, Hallucinogens, Humans, Lysergic Acid Diethylamide, Male, Mental Health, Mescaline, Middle Aged, Psilocybin, Risk Factors, United States, Odds Ratio

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Psychedelics and Mental Health: A Population Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks